<bill session="116" type="h" number="2700" updated="2022-02-08T23:14:47Z">
  <state datetime="2019-05-14">REFERRED</state>
  <status>
    <introduced datetime="2019-05-14"/>
  </status>
  <introduced datetime="2019-05-14"/>
  <titles>
    <title type="display">Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act</title>
    <title type="official" as="introduced">To incentivize low-cost drug options and generic competition, and to provide extensions for community health centers and the National Health Service Corps, and for other purposes.</title>
    <title type="short" as="introduced">Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act</title>
  </titles>
  <sponsor bioguide_id="B001248"/>
  <cosponsors>
    <cosponsor bioguide_id="A000369" joined="2019-10-21"/>
    <cosponsor bioguide_id="B001257" joined="2019-05-14"/>
    <cosponsor bioguide_id="B001311" joined="2019-12-05"/>
    <cosponsor bioguide_id="B001295" joined="2019-05-23"/>
    <cosponsor bioguide_id="B001284" joined="2019-05-14"/>
    <cosponsor bioguide_id="B001275" joined="2019-05-14"/>
    <cosponsor bioguide_id="C001103" joined="2019-05-14"/>
    <cosponsor bioguide_id="C001093" joined="2019-05-14"/>
    <cosponsor bioguide_id="D000600" joined="2019-05-16"/>
    <cosponsor bioguide_id="D000615" joined="2019-05-14"/>
    <cosponsor bioguide_id="F000461" joined="2019-05-14"/>
    <cosponsor bioguide_id="G000584" joined="2019-05-14"/>
    <cosponsor bioguide_id="G000568" joined="2019-05-14"/>
    <cosponsor bioguide_id="G000558" joined="2019-05-14"/>
    <cosponsor bioguide_id="H001088" joined="2019-05-16"/>
    <cosponsor bioguide_id="H001053" joined="2019-11-13"/>
    <cosponsor bioguide_id="H001056" joined="2019-05-17"/>
    <cosponsor bioguide_id="H001072" joined="2019-05-14"/>
    <cosponsor bioguide_id="H001067" joined="2019-05-14"/>
    <cosponsor bioguide_id="H001073" joined="2019-05-14"/>
    <cosponsor bioguide_id="J000292" joined="2019-05-14"/>
    <cosponsor bioguide_id="J000295" joined="2019-06-13"/>
    <cosponsor bioguide_id="K000378" joined="2019-05-14"/>
    <cosponsor bioguide_id="L000566" joined="2019-05-14"/>
    <cosponsor bioguide_id="L000576" joined="2019-05-14"/>
    <cosponsor bioguide_id="L000583" joined="2019-05-16"/>
    <cosponsor bioguide_id="M001198" joined="2019-05-16"/>
    <cosponsor bioguide_id="M001180" joined="2019-05-14"/>
    <cosponsor bioguide_id="M001159" joined="2019-05-14"/>
    <cosponsor bioguide_id="M001187" joined="2019-05-23"/>
    <cosponsor bioguide_id="M001201" joined="2019-05-14"/>
    <cosponsor bioguide_id="M001190" joined="2019-05-14"/>
    <cosponsor bioguide_id="O000168" joined="2019-05-14"/>
    <cosponsor bioguide_id="R000582" joined="2019-05-17"/>
    <cosponsor bioguide_id="S001176" joined="2019-05-14"/>
    <cosponsor bioguide_id="S000244" joined="2019-05-14"/>
    <cosponsor bioguide_id="S000364" joined="2019-05-14"/>
    <cosponsor bioguide_id="S001196" joined="2019-05-16"/>
    <cosponsor bioguide_id="S001187" joined="2019-05-14"/>
    <cosponsor bioguide_id="U000031" joined="2019-05-14"/>
    <cosponsor bioguide_id="W000812" joined="2019-10-29"/>
    <cosponsor bioguide_id="W000798" joined="2019-05-14"/>
    <cosponsor bioguide_id="W000791" joined="2019-05-14"/>
    <cosponsor bioguide_id="W000804" joined="2019-05-23"/>
  </cosponsors>
  <actions>
    <action datetime="2019-05-14">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-05-14" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-05-14">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-05-15">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-06-26">
      <text>Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.</text>
    </action>
    <action datetime="2019-06-26">
      <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSJU" name="House Judiciary" subcommittee="" activity="Referral"/>
    <committee code="HSJU05" name="House Judiciary" subcommittee="Administrative State, Regulatory Reform, and Antitrust" activity="Referral"/>
    <committee code="HSJU03" name="House Judiciary" subcommittee="Courts, Intellectual Property, and the Internet" activity="Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="19" relation="unknown"/>
    <bill session="116" type="h" number="987" relation="unknown"/>
    <bill session="116" type="h" number="3053" relation="unknown"/>
    <bill session="116" type="s" number="192" relation="unknown"/>
    <bill session="116" type="s" number="340" relation="unknown"/>
    <bill session="116" type="h" number="938" relation="unknown"/>
    <bill session="116" type="h" number="965" relation="unknown"/>
    <bill session="116" type="h" number="1499" relation="unknown"/>
    <bill session="116" type="h" number="1943" relation="unknown"/>
    <bill session="116" type="h" number="2668" relation="unknown"/>
    <bill session="116" type="h" number="2680" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Appropriations"/>
    <term name="Child health"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Consumer affairs"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Education programs funding"/>
    <term name="Family planning and birth control"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health facilities and institutions"/>
    <term name="Health personnel"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Indian social and development programs"/>
    <term name="Inflation and prices"/>
    <term name="Judicial review and appeals"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
    <term name="Medical education"/>
    <term name="Medical research"/>
    <term name="Minority health"/>
    <term name="National and community service"/>
    <term name="Prescription drugs"/>
    <term name="Product development and innovation"/>
    <term name="Sex and reproductive health"/>
    <term name="Social work, volunteer service, charitable organizations"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-12T19:32:21Z" status="Introduced in House">Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act 

This bill addresses prescription drugs and extends several health care, research, and workforce programs.

Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met. 

The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product.

The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing.

The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.</summary>
</bill>
